|
시장보고서
Emerging Diagnostic Technologies for Use in Psychiatric Indications
|
Abstract
Introduction
The diagnosis of psychiatric diseases is an inexact science and a slow process
for physicians. No laboratory tests are available to determine the exact
disease-or treatment. New diagnostic technologies could offer earlier, more
specifi c diagnosis of a psychiatric disease and even direct potential drug
therapy. In this report, we discuss the treatment challenges that confront
physicians and patients and review current and emerging diagnostic tests that
are expected to change the way in which psychiatric diseases are diagnosed.
This report also features three Expert Commentaries, two offering input from
the diagnostic technology industry, and one highlighting Decision Resources'
primary research with physicians who discuss their views of biomarkerbased
diagnostic tests for psychiatry.
Get the Answers You Need to Shape Your Strategy
- The diagnosis of mental illness is far from an exact science, with no
laboratory tests to confi rm a disorder or offer treatment strategies. What
technologies are emerging that will expedite diagnosis and treatment of
psychiatric disorders? How will these technologies affect R&D within the
pharmaceutical industry?
- EEG, molecular, genetic, and imaging diagnostics are all poised for use in
the fi eld of psychiatry. How will the technologies that exist to aid
diagnosis expand into the fi eld of mental health? What companies already have
clinical trials under way and what diagnostic tools are they using? How will
these studies target patient response to some of today' s most popular
psychiatric drugs? What challenges do manufacturers face when developing these
diagnostics?
- Expert Commentaries: two company executives and one market analyst discuss
the impact of novel diagnostics in the psychiatric arena. What are thought
leaders saying about the potential for biomarkers in mental health diagnosis
and treatment? How will a new EEG tool help psychiatrists target drug therapy
in their patients? How can gene-expression profi les lead to differential
diagnoses or offer insight into disease-specifi c subtyping?
Scope
- Diffi culties diagnosing mental illness: addressing similar
symptomatology; multiple mental illnesses in one patient; challenges in
determining optimal treatment; current medical practice for psychiatric
indications.
- Current and emerging diagnostic technologies for psychiatric
indications: EEG (Aspect Medical Systems, CNS Response, Memory
Pharmaceuticals/Roche); molecular diagnostics (Clinical Data, CombiMatrix,
Curidium Medica, Roche/Affymetrix, Vanda Pharmaceuticals); diagnostic imaging
(Alseres).
- Psychiatric disorders: attention-defi cit/hyperactivity disorder;
autism spectrum disorder; bipolar disorder; major depression; schizophrenia;
psychotic disorders.
- Business considerations: review of partnerships and licensing
activities; benefi ts of drug/theranostic codevelopment; challenges and
opportunities.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- The Importance of Diagnostic Technologies for Psychiatric Indications
- Value of Biomarker-Based Diagnostics for Psychiatric Diseases
- Diffi culties in Diagnosing Psychiatric Illness
- Presentation of Prodromal Symptoms Can Be Slow and Variable
- Several Disorders May Have Similar Symptomatology
- Patients with Multiple Mental Illnesses May be Diffi cult to Diagnose
- Some Mental Illnesses May Be Broad Categories of Diseases
- Challenges in Determining Optimal Treatment
- Current Medical Practice for Psychiatric Indications
- Current and Emerging Diagnostic Technologies for Psychiatric Indications
- Electroencephalography
- Aspect Medical Systems
- CNS Response
- Memory Pharmaceuticals/Roche and Envivo Pharmaceuticals
- Molecular Diagnostics
- Clinical Data
- CombiMatrix
- Curidium Medica
- Roche/Affymetrix
- Vanda Pharmaceuticals
- Diagnostic Imaging
- Outlook
- Appendix A. Thought Leaders Consulted for This Report
- Appendix B. Bibliography
Expert Commentaries
- What Do Thought Leaders Say About the Potential Use of Biomarkers in
Psychiatric Diagnosis and Treatment?
- Carlos Dedesma, Analyst, Decision Resources, Inc
- The Potential for rEEG to Create Win-Win Situations for Stakeholders
- Leonard Brandt, CEO, CNS Response
- Disentangling Patient Populations to Develop More-Effective Drug Therapies
- Anne T. Bruinvels, Ph.D., Founder and CSO, Curidium Medica
Sidebar
Tables
- 1. Diagnostic Collaborations in Psychiatric Indications, 2004-March 2008
- 2. Roche' s AmpliChip CYP450 Test: Summary of Attributes
- 3. Major Opportunities and Challenges for Psychiatric Diagnostics
- A. Drug Development Benefi ts by Development Phase
Figures
- 1. How Diagnostic Technologies Can Increase Treatment Effi cacy
- 2. Referenced-EEG Sample Report to Physicians from CNS Response
- A. Medications Predicted by rEEG
- B. Schematic Overview of the Studies Undertaken by Curidium to Identify a
Blood Diagnostic Tool to Select Schizophrenia and Bipolar Disorder Patient
Subgroups in the Clinic
|
